Metabolic dysfunction–associated steatohepatitis (MASH) is a severe form of liver disease
that poses a global health threat because of its potential to progress to advanced fibrosis …

Nonalcoholic fatty liver disease (NAFLD) is the dominant cause of liver disease worldwide.
Nonalcoholic steatohepatitis (NASH), a more aggressive presentation of NAFLD, is …

Normothermic machine perfusion (NMP) has emerged as an innovative organ preservation
technique. Developing an understanding for the donor organ immune cell composition and …

Progressive accrual of senescent cells in aging and chronic diseases is associated with
detrimental effects in tissue homeostasis. We found that senescent fibroblasts and epithelia …

Non-alcoholic fatty liver disease (NAFLD) is reaching epidemic proportions, with a global
prevalence of 25% in the adult population. Non-alcoholic steatohepatitis (NASH), which can …

The liver is the central metabolic organ of the body, regulating energy and lipid metabolism,
while also having potent immunological functions. Overwhelming the metabolic capacity of …

Aging increases the risk of liver diseases and systemic susceptibility to aging-related
diseases. However, cell type-specific changes and the underlying mechanism of liver aging …

Nonalcoholic fatty liver disease (NAFLD), a spectrum of metabolic liver disease associated
with obesity, ranges from relatively benign hepatic steatosis to nonalcoholic steatohepatitis …

Nonalcoholic fatty liver disease (NAFLD) has become a common health care burden
worldwide. The high heterogeneity of NAFLD remains elusive and impairs outcomes of …

Nonalcoholic fatty liver disease (NAFLD) is a fast growing, chronic liver disease affecting∼
25% of the global population. Nonalcoholic fatty liver disease severity ranges from the less …